RedHill Biopharma Launches Talicia for H. pylori Infection Treatment.

• Talicia sales and operational launch started by Talicia Holdings Inc. • Joint commercialization agreement between Talicia Holdings and Cumberland. • Focused on unlocking Talicia's full market potential. • Talicia is the only FDA-approved H. pylori therapy addressing antibiotic resistance. • Recommended as first-line H. pylori therapy in ACG Clinical Guideline. • H. pylori infection affects 35% of U.S. adult population. • Estimated 1.6 million U.S. patients treated annually for H. pylori infection.